ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference
04 août 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a...
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021
02 août 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market...
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
06 juil. 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an...
ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference
16 juin 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a...
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
08 juin 2021 08h30 HE
|
ChemoCentryx, Inc.
-- Abstract on ‘The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease’ honored on “Ten Best” list by the Paper...
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
06 mai 2021 23h37 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee...
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
29 avr. 2021 16h05 HE
|
ChemoCentryx, Inc.
-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee...
ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021
22 avr. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market...
ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
09 avr. 2021 08h30 HE
|
ChemoCentryx, Inc.
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the...
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
07 avr. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30...